Anticorps Recombinant de lapin anti-Beta-2-Microglobulin

Beta-2-Microglobulin Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC

Conjugaison

Non conjugué

CloneNo.

241308D5

N° de cat : 98165-1-PBS

Synonymes

B2M, 241308D5, HDCMA22P, CDABP0092, Beta-2-microglobulin form pI 5.3

---

Galerie de données de validation

• 

  FC experiment of human peripheral blood leukocytes using 98165-1-RR (same clone as 98165-1-PBS)

  1x10^6 human peripheral blood leukocytes were surface stained with 0.25 ug Anti-Human B2M Rabbit Recombinant Antibody (98165-1-RR, Clone:241308D5) or 0.25 ug Isotype Control, and PE-Conjugated Goat Anti-Rabbit IgG(H+L). Cells were not fixed. This data was developed using the same antibody clone with 98165-1-PBS in a different storage buffer formulation.

• 

  Affinity and Kinetic Characterization of 98165-1-RR

  Biolayer interferometry (BLl) kinetic assays of 98165-1-RR against Human Beta-2-Microglobulin were performed. The affinity constant is 0.743 nM.

---

Informations sur le produit

98165-1-PBS cible Beta-2-Microglobulin dans les applications de FC et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Protéine recombinante
• Nom complet: beta-2-microglobulin
• Masse moléculaire calculée: 119 aa, 14 kDa
• Numéro d’acquisition GenBank: BC032589
• Symbole du gène: B2M
• Identification du gène (NCBI): 567
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Protein A purfication
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C.

Informations générales

Beta-2-microglobulin (B2M) is a component of MHC class I molecules, which are present on the surface of nearly all nucleated cells. It can be found in body fluids under physiologic conditions due to shedding from cell surfaces or intracellular release. B2M has various biological functions, including antigen presentation. Investigations reveal that increased synthesis and release of B2M are present in several malignant diseases.

{{ptg:RelatedPrimaryAntibodies}}